QUICK LINKS: Resource Order Form
In this section: Publications archive I Home Dialysis Survey I Indigenous kidney health statistics & reports
For Health Professionals: CKD in Australia I Detecting CKD I GFR Calculator (CKD-EPI formula)
Chronic Kidney Disease Management in General Practice
The 2nd edition of our popular CKD Management in General Practice supercedes the previous version and contains important new information.
- New CKD staging system and colour-coded action plans
- New recommendations albuminuria
- New eGFR recommendations
- New blood pressure targets
This book is available for PDF download - or in hard-copy.
You may also order this booklet by using this special Order Form.
When complete, send this form by email, with your contact details to KCAT@kidney.org.au. Overseas order are not available.
Formally endorsed by RACGP, the ANZSN and Kidney Health Australia
Renal Drug Reference Guide
Following introductory principles on the use of drugs in patients with renal impairment, the Renal Drug Reference Guide is structured into 13 colour coded therapeutic chapters including; anaemia, analgaesia, antihistamines, anti-infectives, cardiovascular, endocrine & metabolic disorders, gastrointestinal, genitourinary, immunosuppressants, musculoskeletal, neurology & psychotropics. As well as being evidence based, this information is practical and written expressly for the prescriber who is searching for easy to comprehend, definitive advice.
$77A each - Contact author: Matthew Cervelli +61 408 846 901 or email email@example.com
Edited by Matthew Cervelli, Forward by Dr Tim Mathew (KHA Medical Director) Professor Graeme Russ (Queen Elizabeth Hospital) and published with assistance of Kidney Health Australia and unrestricted support of various pharmaceutical industry partners. Guide intended for healthcare professionals who are able to exercise independent professional clinical judgement when using the information contained within. It is not intended use by healthcare consumers.
|A decade after the KDOQI CKD Guidelines: a perspective from Australia
American Journal of Kidney Disease Volume 60 Issue 5, pages 725-726, November 2012, for full text article
NEW IMPORTANT RESOURCES
My Kidneys - My Choice! Decision Aid Tool
The ‘My Kidneys - My Choice’ Decision Aid has been designed to support patients and their families through the education and decision making process. It is a supplement to education and not a replacement.
This health professional guide is to help you understand how the Decision Aid was designed to be used in practice. It contains some useful hints and tips, as well as background information.
Do you have patients considering Home Dialysis?
A complete education resource about home dialysis, including a developing area specifically for health professionals, can be found at our sister website www.homedialysis.org.au or call our Kidney Health Information Service on 1800 454 363 or email firstname.lastname@example.org
Do you have patients needing information on Kidney Cancer?
Refer patients with questions to our Kidney Cancer Support Service – 1800 454 363 – email email@example.com - or our sister website presents evidence based information for patients at www.kidneycancer.org.au
ABSOLUTE CARDIOVASCULAR RISK GUIDELINES
Australian Guidelines for the management of absolute cardiovascular disease risk (May 2012)
Developed by National Vascular Disease Prevention Alliance (NVDPA) after approval by National Health and Medical Research Council (NHMRC), these guidelines incorporate and build on earlier guidelines (2009) and consolidate other evidence-based guidelines related to primary prevention of cardiovascular disease (CVD).
These guidelines are an important step as they provide a single preventive approach to first-ever CVD in Australia. Clinical decisions based on absolute risk can lead to improved health outcomes by identifying people most at risk and directing the right treatments to them. These resources support these guidelines.
STUDIES COMPLETED IN COLLABORATION WITH KIDNEY HEALTH AUSTRALIA
Projections of the incidence of treated End-Stage Kidney Disease in Australia, 2010-2020
AIHW catalogue number (PHE150)
Internet only - 14 September 2011 INTERNET ONLY ISBN 978-1-74249-201-8; Cat no PHE 150; 64pp
This report presents projections for end-stage kidney disease treated with dialysis or kidney transplantation (treated ESKD) for period 2010 to 2020. Projections are set out by sex at national and state/territory levels, and for ESKD patients with diabetes when commencing treatment.
The incidence of treated ESKD is projected to continue to rise, increasing by nearly 80% between 2009 and 2020 The proportion of those commencing ESKD treatment with diabetes is also expected to increase, from 45% in 2009 to 64% in 2020.
Economic Impact of End-Stage Kidney Disease in Australia - Projections to 2020
Read Executive Summary or full report November 2010
The cost of treating end-stage kidney disease from 2009 to 2020 is estimated to be around $12 billion to the Australian Government. This reports reveals the incidence of kidney disease is growing at a serious rate, projected to increase by more than 54% to 2020. Report estimates that increasing the use of home dialysis over the next 10 years would lead to an estimated net savings of between $378 and $430 million for our health system. Annual costs per person for home dialysis is $49,137, compared to $79,072 for hospital dialysis.
Contributors: Alan Cass, Steven Chadban, Martin Gallagher, Kirsten Howard, Alexandra Jones, Stephen McDonald, Paul Snelling and Sarah White. Corresponding author: Prof Alan Cass, Senior Director, George Institute for Global Health, PO Box M201 (Missenden Road) Sydney 2050 Australia - call 02 9993 4553.
Kidney Health Australia commissioned these reports to establish comprehensive research into the economic burden of kidney disease in Australia. Research undertaken and reports written by The George Institute for International Health in collaboration with University of Sydney, Royal Prince Alfred Hospital, Queen Elizabeth Hospital and ANZDATA Registry.
Burden of Chronic Kidney Disease in Australia 2006 set out in two parts
Economic Impact of End-Stage Kidney Disease in Australia
Cost-effectiveness of Early Detection and Intervention to Prevent Progression of CKD in Australia
Two of a KinD (Kidneys in Diabetes) Access Report
This report concludes that an annual and simple kidney health test (a urine test followed by a blood test for those with excess protein in their urine) would prolong the lives of thousands of type 2 diabetes patients and significantly reduce the need for kidney dialysis and transplantation. Two of a KinD Access Report - Key Findings
"Report commissioned by Kidney Health Australia to quantify the burden of diabetic kidney disease in Australia and the cost effectiveness of screening people with type 2 diabetes - released 17 June 2011
Contributors: Dr Tim Mathew, Medical Director - Kidney Health Australia, Dr Mukesh Haikerwal AO, Professor Stephen Colagiuri - University of Sydney. We thank Dr Jonathan Shaw from Baker IDI Heart and Diabetes Institute, for providing access to unpublished data from AusDiab, and Professor Alan Cass - The George Institute for Global Health, for providing data on previous modelling undertaken on cost effectiveness of screening for CKD. We also thank Brian Livingston and Associate Professor Stephen McDonald - ANZDATA, for their efficiency in assisting with additional data. Research undertaken and report prepared by Deloitte Access Economics for Kidney Health Australia, funded by an unconditional grant from Boehringer Ingelheim. In no way has Boehringer Ingelheim had any part in the direction, analysis or findings contained within this report.
AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE REPORTS (AIHW) - ON KIDNEY DISEASE
Direct link to all AIHW reports on Chronic Kidney Disease (CKD)
New website - Indigenous Observatory AIHW in collaboration with Australian Bureau of Statistics (ABS)
KHA webpage - Indigenous Statistics
Latest AIHW report of interest:
Chronic kidney disease: regional variation in Australia
AIHW 17 October 2013. ISBN 978-1-74249-494-4; Cat. no. PHE 172; 53pp.$10.50
Chronic kidney disease is a common and serious problem in Australia and its management can be resource intensive, particularly for the most severe form of the disease: end-stage kidney disease. Rates of chronic kidney disease vary by geographic location. This report shows: - people from Remote and very remote areas were 2.2 times more likely to die from chronic kidney disease than people from Major cities. - people from Very remote areas were at least 4 times more likely to start kidney replacement therapy (dialysis or kidney transplant) than people from non-remote areas.
Multiple causes of death in Australia: an analysis of all natural and selected chronic disease causes of death 1997-2007 AIHW Canberra 2012. AIHW bulletin no 105. Cat no AUS 159.
This bulletin is the first comprehensive application of multiple causes of death statistics to natural causes of death and specific chronic diseases of public health importance in Australia. Useful for guiding and improving policy for reducing deaths from these chronic diseases and for targeting investment in health prevention. When describing patterns of causes of death using only the underlying cause, important cause information is overlooked. Analyses using multiple cause data complement routine descriptions of mortality that use only the underlying cause and offer broader insight into the disease processes occurring at the end of life.
KHA web: Kidney Check Australia Taskforce (KCAT) I KHA - CARI Guidelines
Patient Education Resources: Kidney Health Resources I Organ Donation I Resource Order Form
This site complies with HONcode standards for trustworthy health information: verify here
Kidney Health Australia is an approved health information partner of
Updated 18 November 2013